--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000756418.md" description: "๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $NVIDIA(NVDA.US) NVIDIA Launches BioNeMo Agent Toolkit for AI-Powered Scientific Discovery๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โžค ๐๐•๐ˆ๐ƒ๐ˆ๐€ unveiled ๐๐ข๐จ๐๐ž๐Œ๐จ ๐€๐ ๐ž๐ง๐ญ ๐“๐จ๐จ๐ฅ๐ค๐ข๐ญ for agentic life sciences workflows.โžค Toolkit combines ๐๐ข๐จ๐๐ž๐Œ๐จ, ๐๐ž๐ฆ๐จ๐ญ๐ซ๐จ๐ง, ๐๐ž๐ฆ๐จ๐‚๐ฅ๐š๐ฐ and ๐Ž๐ฉ๐ž๐ง๐’๐ก๐ž๐ฅ๐ฅ technologies.โžค More than ๐Ÿ“๐ŸŽ companies are already using the platform for scientific discovery.โžค ๐Ž๐ฉ๐ž๐ง๐€๐ˆ and ๐€๐ง๐ญ๐ก๐ซ๐จ๐ฉ๐ข๐œ are integrating BioNeMo into scientific AI workflows.โžค Users include ๐ƒ๐š๐ญ๐š๐›๐ซ๐ข๐œ๐ค๐ฌ, ๐’๐ง๐จ๐ฐ๐Ÿ๐ฅ๐š๐ค๐ž, ๐‹๐ข๐ฅ๐ฅ๐ฒ, ๐’๐œ๐ก๐ซรถ๐๐ข๐ง๐ ๐ž๐ซ and Dassault Systรจmes.โžค Toolkit enables AI agents to perform ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง ๐๐ž๐ฌ๐ข๐ ๐ง, genomics and drug discovery tasks.โžค BioNeMo supports workflows including ๐ฏ๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐ฌ๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐ , target discovery and medical imaging analysis.โžค NVIDIA says agents can compress drug screening timelines from ๐๐š๐ฒ๐ฌ ๐ญ๐จ ๐ฆ๐ข๐ง๐ฎ๐ญ๐ž๐ฌ.โžค Global scientific R&D spending has reached ๐Ÿ‘.๐Ÿ– ๐ญ๐ซ๐ข๐ฅ๐ฅ๐ข๐จ๐ง, with pharma budgets near ๐Ÿ‘๐ŸŽ๐ŸŽ ๐›๐ข๐ฅ๐ฅ๐ข๐จ๐ง annually.โžค University of Washington collaboration achieved ๐Ÿ๐ฑ faster performance for RosettaFold3 workloads.๐Ÿ‘‰ ๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:โžค Expands NVIDIA's presence in the fast-growing ๐€๐ˆ-๐๐ซ๐ข๐ฏ๐ž๐ง drug discovery market.โžค Positions AI agents to automate complex ๐ซ๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก and scientific workflows.โžค Broad ecosystem adoption strengthens NVIDIA's ๐ฅ๐ข๐Ÿ๐ž ๐ฌ๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ AI platform strategy.๐Ÿ‘‰ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ:โžค "Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer. For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science โ€” one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine." โ€” ๐‰๐ž๐ง๐ฌ๐ž๐ง ๐‡๐ฎ๐š๐ง๐ , Founder and CEO of NVIDIA.โžค "Every tool we've built for protein design is only as powerful as the scientists who can efficiently access it. The next leap in science won't come from a single discovery; it will come from the speed of iterative designs and agents that can repeatedly reason through the complexity of biology at a speed humans never could." โ€” ๐ƒ๐š๐ฏ๐ข๐ ๐๐š๐ค๐ž๐ซ, Professor of Biochemistry at the University of Washington School of Medicine and Director of the Institute for Protein Design." datetime: "2026-06-23T13:05:40.000Z" locales: - [en](https://longbridge.com/en/topics/100000000756418.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000756418.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000756418.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" generator: "portal-rs" --- # ๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $NVIDIA(NVDA.US) NVIDIA Launches BioNeMโ€ฆ ### Related Stocks - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [SNOW.US](https://longbridge.com/en/quote/SNOW.US.md) - [ANTH.NA](https://longbridge.com/en/quote/ANTH.NA.md) - [OpenAI.NA](https://longbridge.com/en/quote/OpenAI.NA.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [SDGR.US](https://longbridge.com/en/quote/SDGR.US.md) - [DASTY.US](https://longbridge.com/en/quote/DASTY.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**